Autopsy report · NCT04113863

Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer

“Low enrolment rate”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 5 years 7 months before it stopped.
• 76 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Mario Negri Institute for Pharmacological Research

Sponsor type

University, hospital or other

Conditions

Breast Neoplasm Female

Interventions

all-trans retinoic acid; Anastrozole 1mg

Participants

76

Sites

2

Countries

Italy

Trials that died the same way

• Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor
  “Too low enrolment rate” (93% match in meaning)
• A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)
  “Low enrolment” (87% match in meaning)
• Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan
  “Poor enrolment” (76% match in meaning)
• IGF-1, IGFBP3, ALS Normative Ranges in Healthy Pediatric Spanish Population
  “Participant enrolment was lower than expected” (72% match in meaning)
• A Protocol Comparing Temporary Transvenous Diaphragm Pacing to Standard of Care for Weaning From Mechanical Ventilation
  “Low enrollment rate.” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.